Metastatic Prostate Cancer-Does Treatment of the Primary Tumor Matter?

Journal of Urology

Volumn 176, Issue 4, 2006, Pages 1292-1298

  Swanson, Gregory ^a   Thompson, Ian ^a   Basler, Joseph ^a   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

prostate; prostatic neoplasms

Indexed keywords

ATRASENTAN; FLUTAMIDE; MEDROXYPROGESTERONE ACETATE; NITROSOUREA; PLACEBO;

ANALYTIC METHOD; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CRYOSURGERY; CYTOREDUCTIVE SURGERY; GASTROINTESTINAL CARCINOMA; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; KIDNEY CANCER; LIVER METASTASIS; LUNG METASTASIS; LYMPHADENOPATHY; METASTASIS; ORCHIECTOMY; OVARY CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR;

FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33748115809     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.069     Document Type: Article

References (49)

1. Hiramoto R.N., and Ghanta V.K. Surgical adjuvant chemotherapy of metastatic murine osteosarcoma. Int J Cancer 25 (1980) 393
2. Simpson J.R., Horton J., Scott C., Curran W.J., Rubin P., Fischbach J., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme. results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26 (1993) 239
3. Nitta T., and Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75 (1995) 2727
4. Swanson G.P., Rynearson K., and Symmonds R. Significance of margins of excision on breast cancer recurrence. Am J Clin Oncol (CCT) 25 (2002) 438
5. Winer E.P., Morrow M., Osborne C.K., and Harris J.R. Malignant tumors of the breast. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer. Principles and Practice of Oncology. 6th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1651-1717
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer. an overview of the randomized trials. Lancet 352 (1998) 930
7. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974
8. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era. a meta-analysis. J Clin Oncol 20 (2002) 1248
9. Glehen O., Mohamed F., and Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer. new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5 (2004) 219
10. Temple L.K., Hsieh L., Wong W.D., Saltz L., and Shrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22 (2004) 3475
11. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., Padberg G.W., Voormolen J.H., Hoekstra F.H., et al. Treatment of single brain metastasis. radiotherapy alone or combined with neurosurgery?. Ann Neurol 33 (1993) 583
12. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 49 (1999) 231
13. van Geel A.N., Pastorino U., Jauch K.W., Judson I.R., van Coevorden F., Buesa J.M., et al. Surgical treatment of lung metastases. The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77 (1996) 675
14. Swanson D.A., and Wallace S. Surgery of metastatic renal cell carcinoma and use of renal infarction. Semin Surg Oncol 4 (1988) 124
15. Gottesman J.E., Crawford E.D., Grossman H.B., Scardino P., and McCracken J.D. Infarction-nephrectomy for metastatic renal carcinoma. Urology 25 (1985) 248
16. Kurth K.H., Debruyne F.M.J., Hall R.R., Denis L., Verbaes A., Bollack C., et al. Embolization and postinfarction nephrectomy in patients with primary metastatic renal adenocarcinoma. Eur Urol 13 (1987) 251
17. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R., and European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon alfa based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma. a randomized trial. Lancet 358 (2001) 966
18. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655
19. Elhilali M.M., Gleave M., Fradet Y., Davis L., Venner P., Saad F., et al., The Canadian Urologic Oncology Group. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. BJU Int 86 (2000) 613
20. Ohba K., Omagari K., Nakamura T., Ikuno N., Saeki S., Matsuo I., et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43 (1998) 575
21. Camphausen K., Moses M.A., Menard C., Sproull M., Beecken W.D., Folkman J., et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63 (2003) 1990
22. Hartford A.C., Gohongi T., Fukumura D., and Jain R.K. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site. potential role for host-tumor interaction. Cancer Res 60 (2000) 2128
23. Zagars G.K., Pollack A., and von Eschenbach A.C. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58 (2001) 233
24. Ghavamian R., Bergstralh E.J., Blute M.L., Slezak J., and Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer. a matched comparison. J Urol 161 (1999) 1223
25. Schmeller N., and Lubos W. Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Br J Urol 79 (1997) 226
26. Aus G., Nordenskjold K., Robinson D., Rosell J., and Varenhorst E. Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort. Eur Urol 43 (2003) 627
27. Robnett T.J., Whittington R., Malkowicz S.B., Brereton H.D., Van Arsdalen K., Drach G., et al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 1146
28. Lawton C.A., Winter K., Byhardt R., Sause W.T., Hanks G.E., Russell A.H., et al., Radiation Therapy Oncology Group. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN1+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 28 (1997) 931
29. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate cancer death in patients with lymph node metastasis. Cancer 91 (2001) 66
30. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. results at 10 years of EST 3886. J Urol 169 suppl. (2003) 396 abstract 1480
31. Da Pozzo L., Cozzarini C., Bertini R., Colombo R., Mazzoccoli B., Roscigno M., et al. Radical prostatectomy for node-positive prostate cancer. impact of adjuvant hormone therapy and radiotherapy. J Urol 169 suppl. (2003) 494 abstract 1850
32. Cadeddu J.A., Partin A.W., Epstein J., and Walsh P.C. Stage D1 (T1-3, N1-3, M0) prostate cancer. a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50 (1997) 251
33. Pilepich M.V., Krall J.M., al-Sarraf M., John M.J., Doggett R.L., Sause W.T., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma. a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45 (1995) 616
34. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). a phase III randomised trial. Lancet 360 (2002) 103
35. Roach III M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904
36. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate specific antigen testing. 15-year outcome. BJU Int 95 (2005) 751
37. Kadmon D., Heston W.D., and Fair W.R. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 127 (1982) 1238
38. Henry J.M., and Isaacs J.T. Relationship between tumor size and the curability of metastatic prostate cancer by surgery alone or in combination with adjuvant chemotherapy. J Urol 139 (1988) 1119
39. Swanson G.P., Riggs M., and Earle J. Failure after primary radiation or surgery for prostate cancer. differences in response to androgen ablation. J Urol 172 (2004) 525
40. Thompson I.M., Tangen C., Basler J., and Crawford E.D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168 (2002) 1008
41. Carducci M., Nelson J.B., Saad F., Schulman C.C., Dearnaley Sleep D.J., et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer. phase 3 study. J Clin Oncol 22 suppl. (2004) 4508
42. Hu J.C., Gold K.F., Pashos C.L., Mehta S.S., and Litwin M.S. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 169 (2003) 1443
43. Sallah S., and Gagnon G. A reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 18 (2000) 191
44. Palapattu G.S., Kristo B., and Rajfer J. Paraneoplastic syndromes in urologic malignancy. the many faces of renal cell carcinoma. Rev Urol 4 (2002) 163
45. Giri D., Ozen M., and Ittman M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159 (2001) 2159
46. Iwamura M., Abrahamsson P.A., Foss K.A., Wu G., Cockett A.T., and Deftos L.J. Parathyroid hormone-related protein. a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43 (1994) 675
47. Sehgal I., Powers S., Huntley B., Powis G., Pittelkow M., and Maihle N.J. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 91 (1994) 4673
48. Suzuki T., Moriya T., Ishida T., Ohuchi N., and Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother 57 (2003) 460
49. Negri-Cesi P., and Motta M. Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 51 (1994) 89